AD-221B

AD-221B is a component of the fixed-dose combination drug AD-221, which is developed by Addpharma for the treatment of primary hypercholesterolemia and hyperlipidemia. While detailed information about the specific composition or mechanism of action of AD-221B alone is not publicly available, clinical trial records indicate that it was evaluated as a separate arm in studies comparing its efficacy and safety to other related formulations (AD-221A, AD-221C) and to the fixed-dose combination product (AD-221). The parent product, AD-221, is an incrementally modified drug classified as an antihyperlipidaemic agent. In at least one source, the fixed-dose combination contains atorvastatin 5mg and ezetimibe 10mg; however, it is unclear if these are also present in AD-221B specifically[3][5][8]. The developer and sponsor for all related clinical trials is Addpharma.